Mesoblast Target of Unusually High Options Trading (NASDAQ:MESO)

Mesoblast Limited (NASDAQ:MESO) was the recipient of some unusual options trading activity on Thursday. Traders purchased 3,838 put options on the stock. This represents an increase of 350% compared to the average daily volume of 852 put options.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Maxim Group upgraded shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, September 24th. StockNews.com cut Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Jefferies Financial Group raised Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, August 29th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. Finally, Piper Sandler boosted their price objective on Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.50.

Institutional Investors Weigh In On Mesoblast

Several institutional investors have recently bought and sold shares of the company. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Mesoblast during the second quarter valued at approximately $80,000. Rathbones Group PLC purchased a new stake in shares of Mesoblast during the second quarter worth approximately $95,000. XTX Topco Ltd acquired a new position in Mesoblast in the 2nd quarter valued at $103,000. Marshall Wace LLP purchased a new position in Mesoblast in the 2nd quarter valued at $562,000. Finally, Lazari Capital Management Inc. boosted its stake in Mesoblast by 6.6% during the 2nd quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock worth $364,000 after purchasing an additional 3,300 shares during the last quarter. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Stock Performance

MESO stock opened at $16.76 on Friday. Mesoblast has a 52 week low of $1.61 and a 52 week high of $19.15. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The firm has a 50-day simple moving average of $10.24 and a 200-day simple moving average of $8.17.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.